The diagnosis and management of psoriatic arthritis in a professional football player presenting with a knee effusion: A case report

Clinical Journal of Sport Medicine

Volumn 18, Issue 4, 2008, Pages 369-371

  Brophy, Robert H ^a,e   MacKenzie, C Ronald ^b   Gamradt, Seth C ^c   Barnes, Ronnie P ^d   Rodeo, Scott A ^b   Warren, Russell F ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d NEW YORK GIANTS   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

Athlete; DMARD; Punter; Seronegative spondyloarthropathy

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; ATHLETE; CASE REPORT; DEBRIDEMENT; ERYTHROCYTE SEDIMENTATION RATE; FOOTBALL; HUMAN; JOINT EFFUSION; JOINT SWELLING; KNEE; KNEE ARTHROSCOPY; KNEE INJURY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATELLA CHONDROMALACIA; PATELLOFEMORAL JOINT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SYNOVITIS; EXUDATE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; EXUDATES AND TRANSUDATES; FOOTBALL; HUMANS; HYDRARTHROSIS; IMMUNOGLOBULIN G; KNEE JOINT; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 49049114791     PISSN: 1050642X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815fa7a6     Document Type: Article

References (14)

1. Bennett RM. Psoriatic arthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology. Koopman WJ and Moreland LW, eds. Philadelphia: Lippincott Wilkins & Wilkins; 2002.
2. Bruce IN. Psoriatic arthritis clinical features. In: Rheumatology. Hochberg ML, Silman AJ, Smolen JS, et al. Philadelphia: Mosby; 2004.
3. McClusky OE, Lordon RE, Arnett FC Jr. HL-A 27 in Reiter's syndrome and psoriatic arthritis: a genetic factor in disease susceptibility and expression. J Rheumatol. 1984;11:571.
4. Moll JMH, Wright V. Psoriatic arthritis. Semin Arth Rheum. 1973;3: 55-78.
5. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2013-2020.
6. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-1950.
7. Espinoza LR, Zakraoui L, Espinoza CG, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992;19: 872-877.
8. Lee JC, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7: 160-165.
9. Cauza E, Spak M, Cauza K, et al. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. 2002;22:227-232.
10. Raffayová H, Rovenský J, Mális F. Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment. Int J Clin Pharmacol Res. 2000;20:1-11.
11. Marguerie L, Flipo RM, Grardel B, et al. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine. 2002;69:275-281.
12. Prasad R, Gladman D. Current and investigational treatment of psoriatic arthritis. Expert Opin Investig Drugs. 2004;13:139-150.
13. Wong VK, Lebwohl MG. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist. Expert Opin Biol Ther. 2005;5:1505- 1513.
14. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol. 2007;25: 563-567.